Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin VANCOUVER, British Columbia, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...

Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr. Brian Barnett to its newly formed Medical Advisory Board. Dr. Wright...

CB Therapeutics and atai Life Sciences launch TryptageniX to sustainably supply and develop clinically relevant compounds to tackle the growing mental health crisis SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics, a biosynthesis company focused on creating ethical and environmentally-friendly products to improve mental health and increase...

Psychedelic Drugs Market CAGR at +13.3% with Analysis of Growing Technology Trends, Industry Research, Future Growth and Size, Projection by 2028 SAN FRANCISCO, July 14, 2021 (GLOBE NEWSWIRE) -- Psychedelic Drugs Market Research Report gives insightful analysis of the market along with its comprehensive understanding and its commercial...